ArticleSurgical endoscopy2026
Performance and safety of the Colovac 2 colorectal anastomotic protection device: the SafeHeal SAFE-2023 study.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06540807 (SafeHeal Anastomosis Feasibility Evaluation), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
SafeHeal Anastomosis Feasibility Evaluation (SAFE)-2023 Study: A Study to Investigate the Performance and Safety of the Colovac 2 Colorectal Anastomosis Protection Device
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTemporary diverting ostomies have become the predominant approach to reduce anastomotic leakage (AL) after anterior resection. Colovac Device is an anastomosis protection device designed to divert feces from the anastomosis. This study evaluated a new version of the Colovac Device (Colovac 2), used with the novel SmartVac Vacuum Management Device, which is used to anchor the device in the colon.
methodsThe SAFE-2023 Study was a prospective, multicenter single-arm study that enrolled patients undergoing low anterior resection (LAR) and Colovac placement. The primary performance endpoint was to assess the clinically significant (CS) migration rate of the device through device retrieval. The other performance endpoints were ostomy avoidance rate at Day 10 visit, and fecal diversion success as assessed by cleanliness of the colon immediately prior to device retrieval.
resultsA total of 24 patients were enrolled. 100% (24/24) of the Colovac devices were successfully placed in the intended location, and 100% were successfully removed endoscopically without complications. CS migration occurred in 2 patients (8.3%) on POD8 and POD9, respectively. In both cases, the device was successfully retrieved without complications, good anastomotic healing was confirmed, and no ostomy conversion was performed. The ostomy avoidance rate was 87.5% (21/24) at Day 10 and 83% (20/24) at Day 30 post-device placement. Fecal diversion success assessed immediately prior to device retrieval was 95.8% (23/24).
conclusionsThe SAFE-2023 study demonstrated a low CS migration rate for the Colovac. The Colovac Device provides a minimally invasive option to protect the anastomosis during the healing process by avoiding the need for a diverting ostomy in 87.5% of patients at Day 10.
trial registrationSAFE-2023: NCT06540807.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.